BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24849384)

  • 1. Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: a retrospective study of switching from intranasal desmopressin.
    Murakami T; Hatoko T; Nambu T; Matsuda Y; Matsuo K; Yonemitsu S; Muro S; Oki S
    Endocr J; 2014; 61(8):773-9. PubMed ID: 24849384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study.
    Arima H; Oiso Y; Juul KV; Nørgaard JP
    Endocr J; 2013; 60(9):1085-94. PubMed ID: 23811987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.
    Kataoka Y; Nishida S; Hirakawa A; Oiso Y; Arima H
    Endocr J; 2015; 62(2):195-200. PubMed ID: 25382102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comments on "Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study"--efficacy and safety of orally disintegrating desmopressin tablets in patients with central diabetes insipidus.
    Kamoi K
    Endocr J; 2013; 60(9):1115. PubMed ID: 23863202
    [No Abstract]   [Full Text] [Related]  

  • 5. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial.
    Yamaguchi O; Nishizawa O; Juul KV; Nørgaard JP
    BJU Int; 2013 Mar; 111(3):474-84. PubMed ID: 23046147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
    Yamaguchi O; Juul KV; Falahati A; Yoshimura T; Imura F; Kitamura M
    Low Urin Tract Symptoms; 2020 Jan; 12(1):8-19. PubMed ID: 31397969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients.
    Juul KV; Schroeder M; Rittig S; Nørgaard JP
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2181-7. PubMed ID: 24527719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Practice Changes After Post-Market Safety Reports on Desmopressin Orally Disintegrating Tablet in Japan: A Single-Center Retrospective Study.
    Yasuda T; Murakami T; Yasoda A; Sone M; Harada N; Ogura M; Inagaki N
    J Clin Med Res; 2021 Feb; 13(2):92-100. PubMed ID: 33747323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency.
    Hoshino Y; Inoue K; Ikeda S; Goshima Y; Tatsushima K; Fukuhara N; Okada M; Nishioka H; Yamada S; Takeuchi Y; Takeshita A
    J Clin Endocrinol Metab; 2024 Feb; 109(3):e983-e996. PubMed ID: 38019190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus.
    Mavinkurve M; McGrath N; Johnston N; Moloney S; Murphy NP; Hawkes CP
    J Pediatr Endocrinol Metab; 2017 May; 30(6):623-628. PubMed ID: 28599389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with sublingual desmopressin in two infants with hydranencephaly and central diabetes insipidus].
    Marín GR; Baspineiro B; Vilca I
    Arch Argent Pediatr; 2018 Feb; 116(1):e93-e97. PubMed ID: 29333830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in Oral Desmopressin Dose Requirements in Children with Central Diabetes Insipidus.
    Almutlaq N; Eugster EA
    J Pediatr; 2021 Dec; 239():228-230. PubMed ID: 34487771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy.
    Smego AR; Backeljauw P; Gutmark-Little I
    J Clin Endocrinol Metab; 2016 May; 101(5):2084-8. PubMed ID: 27011115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
    Sand PK; Dmochowski RR; Reddy J; van der Meulen EA
    J Urol; 2013 Sep; 190(3):958-64. PubMed ID: 23454404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of central diabetes insipidus with oral desmopressin lyophilisate in infants.
    Korkmaz HA; Demir K; Kılıç FK; Terek D; Arslanoğlu S; Dizdarer C; Ozkan B
    J Pediatr Endocrinol Metab; 2014 Sep; 27(9-10):923-7. PubMed ID: 24854529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
    Weiss JP; Herschorn S; Albei CD; van der Meulen EA
    J Urol; 2013 Sep; 190(3):965-72. PubMed ID: 23454402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria.
    Weiss JP; van der Meulen EA; Juul KV
    Eur Urol Focus; 2020 Sep; 6(5):1006-1012. PubMed ID: 30470646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus.
    Juul KV; Bichet DG; Nørgaard JP
    Endocrine; 2011 Aug; 40(1):67-74. PubMed ID: 21626284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
    Kim RJ; Malattia C; Allen M; Moshang T; Maghnie M
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis.
    Juul KV; Van Herzeele C; De Bruyne P; Goble S; Walle JV; Nørgaard JP
    Eur J Pediatr; 2013 Sep; 172(9):1235-42. PubMed ID: 23677249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.